Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.

"CONFLICTS OF INTEREST Ronald J. Sokol advises and consults for Albireo. He advises Mirum. He consults for Alexion. Emmanuel M. Gonzales consults for and advises Albireo and Mirum. He consults for Laboratoires CTRS and Vivet Therapeutics. Binita M. Kamath consults for and received grants from Mirum and Albireo. She consults for Audentes. Alastair Baker received grants from Mirum and Albireo. Pamela Vig owns stock in and is employed by Mirum. Douglas B. Mogul owns stock in and is employed by Mirum. Will Garner owns stock in and is employed by Mirum. Bettina E. Hansen consults for and received grants from Intercept, Calliditas, and Cymabay. She consults for Ipsen, Alberio, Mirum, Enyo, and Eiger. Emmanuel Jacquemin consults for Laboratoire CTRS and Vivet Therapeutics. Richard J. Thompson consults for and owns stock in GenerationBio and Rectify Therapeutics. He consults for Mirum and Albireo."

"FUNDING INFORMATION This study was supported by Mirum Pharmaceuticals Inc."